Want to see AIMD full AI Analyst Report?
AIMD Stock Chart & Stats
$1.40
-$0.05(-3.57%)
At close: 4:00 PM EDT
$1.40
-$0.05(-3.57%)
Day’s Range― - ―
52-Week Range$1.26 - $4.44
Previous CloseN/A
Volume31.95K
Average Volume (3M)78.00K
Market Cap
$10.71M
Enterprise Value$26.66
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$13.81M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding7,384,073
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Nose Platform AdvancementUpgrades across sensing hardware, software and edge computing could improve reliability and support broader commercial deployment. A more robust platform may strengthen Ainos’ ability to convert its Chemical Intelligence technology into recurring industrial applications.
Expanding Chemical Intelligence DatasetRapid growth in real-world chemical data can improve model development and sensing performance, potentially creating a data-based competitive advantage. The semiconductor and operating-environment focus also supports relevance to demanding industrial use cases.
New Environmental Sensing PlatformAtmosphere Engine expands Ainos beyond standalone sensing into active environmental management and industrial infrastructure. Targeting data centers and semiconductor plants could diversify the platform’s opportunity set if the technology achieves commercial validation.
Bears Say
Persistent UnprofitabilityVery low and declining revenue is not currently sufficient to support the cost base, while recurring losses indicate no demonstrated path to breakeven. Sustained unprofitability may constrain product investment and increase dependence on external funding.
Ongoing Cash BurnNegative operating and free cash flow show that the business is not self-funding its operations or development programs. Unless commercialization improves materially, continued cash consumption could require additional borrowing or equity financing.
Deteriorating Balance SheetA sharply smaller equity cushion and higher leverage reduce financial flexibility as losses continue. The short-term credit facility provides liquidity, but the underlying balance-sheet deterioration leaves less capacity to absorb execution or funding setbacks.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.44 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $10.71M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is Nov 11, 2026 which is in 81 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on Aug 03, 2026. The company reported -$0.624 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 7,384,073 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.624 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.759%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―
Ownership Overview
48.13% Insiders
0.43% Mutual Funds
0.37% Other Institutional Investors
50.85% Public Companies and
Individual Investors